Treatment of Chronic Renal Failure With Adipose Tissue-derived Mesenchymal Stem Cells (NCT03321942) | Clinical Trial Compass
UnknownNot Applicable
Treatment of Chronic Renal Failure With Adipose Tissue-derived Mesenchymal Stem Cells
China100 participantsStarted 2017-01-01
Plain-language summary
To investigate the biological characteristics of adipose tissue-derived mesenchymal stem cells(AMSCs) and its treatment effects on chronic renal failure.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Enroll the chronic renal failure patients without dialysis in the department of nephrology of Affiliated Hospital of Xuzhou Medical University from January 2017 to December 2018.
* The patients enrolled were not treated with drugs that affect the renal blood flow and oxygen consumption, such as ACEI, ARB, calcium channel blockers, diuretics, vasodilators and other related factors within 2 weeks.
Exclusion Criteria:
* Exclude those patients with diabetes, cardiovascular disease, severe infection, shock, dehydration, abnormal liver function, received glucocorticoid therapy, surgery and emergency dialysis.
* Eliminate those patients with respiratory disease(such as chronic obstructive pulmonary disease, bronchiectasis, asthma), cardiovascular diseases(such as acute and chronic cardiac insufficiency), blood system diseases (such as aplastic anemia, nutritional anemia and polycythemia vera).
What they're measuring
1
serum creatinine
Timeframe: after 3 months of adipose tissue-derived mesenchymal stem cells treatment
Trial details
NCT IDNCT03321942
SponsorThe Affiliated Hospital of Xuzhou Medical University